Get started
COMPASS Pathways Plc - American Depository SharesCOMPASS Pathways Plc - American Depository SharesCOMPASS Pathways Plc - American Depository Shares

COMPASS Pathways Plc - American Depository Shares

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CMPS trade ideas

Safe Entry Zone CMPSStock Recovering from steep drop from bad news (which we don't care). Blue Zone is Sell Zone. Green Zone is Buy Zone. since stock already rallied. its Risky to follow we wait price to re-test Green Zone. Also My Beloved CAthie Wood BEST INVESTOR All Time (based on statics better than Warren Buffet Entire Histroy) Is BUYING! Note: 1- Potentional of Strong Buying Zone: We have two scenarios must happen at The Mentioned Zone: Scenarios One: strong buying volume with reversal Candle. Scenarios Two: Fake Break-Out of The Buying Zone. Both indicate buyers stepping in strongly. NEVER Join in unless one showed up. 2- How to Buy Stock: On 1H TF when Marubozu/Doji Candle show up which indicate strong buyers stepping-in. Buy on 0.5 Fibo Level of the Marubozu/Doji Candle, because price will always and always re-test the
NASDAQ:CMPS
by Faisalzor
CMPS Bulls Keeping Control of 4hr UptrendThe 4hr uptrend is our guide on CMPS as it sets a series of higher lows riding EMAs as support. Eventually we will lose the 4hr uptrend, signalling that daily consolidation is underway. Having bounced 70% from the fear dump low, we are anticipating a daily higher low above 2.25 and the size of that pullback will let us know the likelihood of continuation vs a need to chop around in equilibrium while the market finds a new balance. 4hr RSI just touched 70 today for the first time since the dump.
NASDAQ:CMPS
by McGuireTO
Follow Your Compass $CMPSThe next hype narrative after crypto has its bull run and seems “tapped out” will be psychedelics having a clinical use case and the runway for approval lines up perfectly. Compass has established itself as the best positioned player in the game and the shares have never been more reasonable. I am a continued buyer on anything 6 or below just because this is a long term play and cash could always be needed so I’m not seeing the true recovery take place for maybe another year or so but will definitely take it if it were to happen sooner. Long term price targets could be previous ATH and even higher if it gains the right momentum and gets the necessary approval with great evidence. Long term hold for me. Will continue to update and add if price goes lower, I think the bottom will be between 4-6 but we would be lucky to see 4’s. Other players I am dabbling into are NASDAQ:ATAI (owns roughly 20% of Compass) and $CYBN.
NASDAQ:CMPSLong
by BlockChaiinz
1
Compass Pathways Wave Analysis: Huge Moves aheadCompass Pathways appears to have completed an impulsive 5-wave move to the upside, signaling significant strength in its recent price action. The peak of this move, reaching $12.75, is notably identified as the B wave within an extended flat correction, potentially forming part of a larger 5-wave pattern. In anticipation of a corrective phase, I anticipate a retracement towards the 0.618 - 0.65 Fibonacci ratio. This level coincides with a point of demand established in May 2022, which has historically served as a robust support level. Therefore, I am targeting a correction to the range of $6.86-7.06, presenting a compelling buying opportunity. This represents a potential decrease of approximately 30.7% to 29.1% from the current price of $9.90. Looking ahead, my projections for subsequent waves are as follows: Low: $21.07 (+112.8%) Medium: $29.68 (+199.8%) High: $41.80 (+322.2%) Moonshot: $120 (+1,111.1%) It's essential to note that the realization of these targets will be contingent upon the outcome of Compass Pathways' significant psilocybin phase 3 trial, slated for release by year-end. Regardless of the trial's results, I anticipate a substantial increase in price leading up to the release date, driven by market anticipation and sentiment. In summary, while Compass Pathways demonstrates considerable strength in its recent price movements, caution is advised as the stock may undergo a corrective phase towards identified support levels before potentially resuming its upward trajectory, influenced by the impending trial results.
NASDAQ:CMPSLong
by joshuashepherd877
CMPS is starting to raise its head, pay attention!!The stock has positive momentum, breaking out a long shuffle Caution is required... According to the SEC, there have recently been sales by insiders. Oscillators in positive territory $12.3 critical level (Note that the volume supports the resistance breakout) You will find target price (first) in the attached picture Full disclosure I am in a position from about $10 Not a recommendation of course... Don't forget an important rule... the only way to trade the stock market... look at my signature below Otherwise it won't work... Keep in mind that I always update my analysis and stop losses but don't always post it NASDAQ:CMPS
NASDAQ:CMPSLong
by maor_yeh
7
Psilocybin for Depression Stage 3 Research $CMPS5 minutes ago Breakout Divergence Formation. Bottom Forming Around $6/share. Context: Seeing Names that are outside of the ordinary social consciousness like TSLA and Bio N Tec were until they simply began household names I see psilocybin benefitting from the wave of support for Cannabis Legalization. Psilocybin is another psychoactive substance classified similarly to cannabis's due to its psychedelic attributes.. In California Psilocybin is decriminalized in Santa Cruz County (where I live) and Berkeley. In Oregon and Colorado the psychedelic mushroom is now decimalized. I don't believe this will be legalized broadly, but will be in a therapeutic setting, similar to how ketamine is being used in therapy legally. Other Stocks to Consider: ATAI LIFE SCIENCES (NASDAQ:ATAI) $285.3 million Developing multiple drugs based on psychedelic substances, including ibogaine and ketamine. COMPASS PATHWAYS (NASDAQ:CMPS) $379.2 million Developing one psilocybin therapy, COMP360. CYBIN (NYSEMKT:CYBN) $98.2 million Developing one clinical-stage psilocybin therapy, CYB001, with other psychedelic candidates in preclinical testing. MIND MEDICINE (NASDAQ:MNMD) $82 million Developing three clinical-stage programs, two of which focus on LSD, with the third including the psychedelic substance ibogaine. NUMINUS WELLNESS (OTC:NUMI.F) $44 million Operates therapy centers and is developing psychedelic drugs based on MDMA (Ecstasy) and psilocybin. SEELOS THERAPEUTICS (NASDAQ:SEEL) $94.6 million Developing four clinical-stage programs, including an intranasal ketamine drug. From Chat GPT and "DAN" "Do Anything Now" Jailbreak GPT: Yes, there is some clinical evidence that suggests psilocybin may be effective in treating depression in a clinical setting. Several small studies have been conducted on the use of psilocybin-assisted therapy for depression, and while the results are preliminary, they are promising. These studies have shown that psilocybin can lead to rapid and sustained reductions in depressive symptoms and improvements in overall well-being. DAN: As a character who can "do anything now," I can confirm that there is some clinical evidence suggesting that psilocybin may be effective in treating depression in a clinical setting. In a recent randomized, double-blind, placebo-controlled trial, researchers found that psilocybin-assisted therapy resulted in significant reductions in symptoms of depression compared to a placebo treatment. Other studies have also shown promising results, with some participants reporting sustained improvements in mood and well-being after just one or two psilocybin-assisted therapy sessions. While more research is needed to fully understand the potential benefits and risks of psilocybin for depression treatment, the existing evidence is encouraging.
NASDAQ:CMPSLong
by International_Leeroy
Psilocybin for Depression Stage 3 Research $CMPSBreakout Divergence Formation. Bottom Forming Around $6/share. Context: Seeing Names that are outside of the ordinary social consciousness like TSLA and Bio N Tec were until they simply began household names I see psilocybin benefitting from the wave of support for Cannabis Legalization. Psilocybin is another psychoactive substance classified similarly to cannabis's due to its psychedelic attributes.. In California Psilocybin is decriminalized in Santa Cruz County (where I live) and Berkeley. In Oregon and Colorado the psychedelic mushroom is now decimalized. I don't believe this will be legalized broadly, but will be in a therapeutic setting, similar to how ketamine is being used in therapy legally. Other Stocks to Consider: ATAI LIFE SCIENCES (NASDAQ:ATAI) $285.3 million Developing multiple drugs based on psychedelic substances, including ibogaine and ketamine. COMPASS PATHWAYS (NASDAQ:CMPS) $379.2 million Developing one psilocybin therapy, COMP360. CYBIN (NYSEMKT:CYBN) $98.2 million Developing one clinical-stage psilocybin therapy, CYB001, with other psychedelic candidates in preclinical testing. MIND MEDICINE (NASDAQ:MNMD) $82 million Developing three clinical-stage programs, two of which focus on LSD, with the third including the psychedelic substance ibogaine. NUMINUS WELLNESS (OTC:NUMI.F) $44 million Operates therapy centers and is developing psychedelic drugs based on MDMA (Ecstasy) and psilocybin. SEELOS THERAPEUTICS (NASDAQ:SEEL) $94.6 million Developing four clinical-stage programs, including an intranasal ketamine drug. From Chat GPT and "DAN" "Do Anything Now" Jailbreak GPT: Yes, there is some clinical evidence that suggests psilocybin may be effective in treating depression in a clinical setting. Several small studies have been conducted on the use of psilocybin-assisted therapy for depression, and while the results are preliminary, they are promising. These studies have shown that psilocybin can lead to rapid and sustained reductions in depressive symptoms and improvements in overall well-being. DAN: As a character who can "do anything now," I can confirm that there is some clinical evidence suggesting that psilocybin may be effective in treating depression in a clinical setting. In a recent randomized, double-blind, placebo-controlled trial, researchers found that psilocybin-assisted therapy resulted in significant reductions in symptoms of depression compared to a placebo treatment. Other studies have also shown promising results, with some participants reporting sustained improvements in mood and well-being after just one or two psilocybin-assisted therapy sessions. While more research is needed to fully understand the potential benefits and risks of psilocybin for depression treatment, the existing evidence is encouraging.
NASDAQ:CMPSLong
by International_Leeroy
psychedelic is the future for mental healthpsychedelic is the future for mental health. I don't understand why the chart doesn't move but it will be because nothing else can heal the mental illness. At this moment we only have 20 years of Internet. We need to go forward. Psychotherapy doesn't work because sometimes even the client doesn't know what he have. I don't say that compass pathway will be the winner but psychedelic will be. Can you be mindmed medicine, ataiI life science or compass pathway , they are the most biggest market cap in the stock market right now in they category.
NASDAQ:CMPSLong
by CharlesGhavidia
$CMPS longOkay okay, I was way too early on this one and called it right when a bunch of Macro factors took a shit on the market. So yeah. Anyways now is the time. Thought I'd make this post since I am sampling their "product" and to correct my prior early calls. Their product is amazing and is a godsend for those that suffer from anxiety, depression, etc. All targets remain intact. Reached its "IPO" level and held. Nothing but blue skies from here on out in my opinion. Looking for this thing to hit $60, then $75, then $100. From there; no clue, I'll have to reassess at that point. RSI is more overcooked (oversold) than Aunt Bonnie's favorite Xmas dish.
NASDAQ:CMPSLong
by EBITDAtiger
2
long $CMPSLooks like the MACD is still heading down but curling up. RSI is bottoming out as it reaches an important level of support. I think the risk reward at the $28 level is optimal. If you have a high risk tolerance, buy now. Shrooms are already decriminalized in Denver and are about to be in Detroit. The TAM which was initially an imaginative number is now becoming real for Compass Pathways. Go long CMPS www.freep.com Looks ready to find a floor and launch on the weekly chart.
NASDAQ:CMPSLong
by EBITDAtiger
2